Rodriguez-Nava, 313 patient HCQ late treatment study: 6% higher mortality [p=0.77] https://c19p.org/rodrigueznava
copied to clipboard
Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support, showing unadjusted RR 1.06, p = 0.77. Confounding by indication likely.
|
risk of death, 6.3% higher, RR 1.06, p = 0.77, treatment 22 of 65 (33.8%), control 79 of 248 (31.9%), unadjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely, excessive unadjusted differences between groups, unadjusted results with no group details.
Rodriguez-Nava et al., 11/5/2020, retrospective, USA, North America, peer-reviewed, median age 68.0, 8 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.